

## FORM 7

### **MONTHLY PROGRESS REPORT**

Name of CNSX Issuer: Cannabix Technologies Inc. (the "Issuer").

Trading Symbol: BLO

Number of Outstanding Listed Securities: 114,144,104 common shares

Date: for September 5, 2022

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNSX.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional. \*See cautionary note on forward looking statements at the end of this report.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The issuer, "Cannabix Technologies Inc.", or "Cannabix", or "the Company" is developing marijuana breathalyzer devices for various markets including law enforcement and employers. All products are at the prototype development stage.

2. Provide a general overview and discussion of the activities of management.

Cannabix Technologies is developing a diversified portfolio of breath testing technologies to detect Tetrahydrocannabinol. Cannabix has filed its own provisional and non-provisional patent applications in relation to various aspects of its intellectual property, and are under review by US and Canadian patent offices. The Company's intellectual property stems from its ongoing research and development activities.

The Company has been granted US Patent 14,689,434 entitled, "Cannabis Drug Detection Device."

The Company has been granted patent No. 2,887,841 entitled, "*Cannabis Drug Detection Device*" from the Canadian Intellectual Property Office.

The Company has been granted US patent No. 17/019,728 entitled, "*Apparatus and Methods for Detection of Molecules*".

The Company has licensed US Patent 8,237,118 (field of use is the exclusive worldwide rights in breath analysis of controlled substances) from the University of Florida.

The Company is working to identify Tetrahydrocannabinol (known as "THC"- the psychoactive component of marijuana that causes impairment) in breath sample ranges using *high-field ion mobility and mass spectrometry*, known as "FAIMS" and FAIMS-mass spectrometer systems (FAIMS-MS). The objective is to develop a FAIMS based drug screening device that would be used by law enforcement, laboratories and other end users to detect cannabis from breath. The Company is (a) characterizing its FAIMS device to establish repeatable results, improve resolving power and separation-discrimination capability, and (b) developing a portable FAIMS device. FAIMS technology filters unwanted ions/analytes and allows select ions to pass through for detection. The characterization work has been conducted using a bench version of the FAIMS device. Cannabix scientists have been actively tuning the FAIMS device coupled to real time switchable mass spectrometry to detect key molecules and their complex pathways in the body and identify recent cannabis use. In addition, the Company is developing technology to effectively capture human breath samples for analysis. The "FAIMS" device is at the prototype development stage.

Cannabix has licensed patent pending technology and from the University of British Columbia. Through its independent research and development efforts, the Company it has developed marijuana breathalyzer system, also known as a "THC Breath Analyzer". The THCBA is being developed as a point of care device for detection of THC from breath that would be ideally suited for workplace and other markets. The "THC Breath Analyzer" is at the prototype development stage.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

During the month the Company announced information related to testing a supplemental

version of its FAIMS technology for detection of  $\Delta$ 9-tetrahydrocannabinol (“THC”) and related analytes in human breath in new comprehensive multi-analysis study of subjects under the influence of marijuana in the southern United States (see July 12, 2022 news release). In the Southern US study using the Company’s technology (BCU and MS Breath Sampler) is being used side by side with several conventional drug screening methods (blood, oral fluid etc.). In June and July, Cannabix participated in two testing day events held in two different US cities. Early study data is demonstrating very consistent correlation of levels of THC between breath samples collected and analyzed with Cannabix hardware and the current standard of whole blood. This is important because blood (measurements) is currently the standard of measurement for drug determination by law enforcement and toxicologists, and is used as objective evidence of possible impairment in courts of law. The Company’s breath collection and analysis method (thus far used in several small preliminary tests) shows very good correlation to blood, which is the standard method to detect and confirm acute cannabis use in the field.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

There were no products or services discontinued during the month.

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None to report.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to report.

8. Describe the acquisition of new customers or loss of customers.

None to report.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None to report.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None to report.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

There were no legal proceedings to which the Issuer became a party during the month.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

There was no new indebtedness incurred or repaid by the Issuer during the month.

14. Provide details of any securities issued and options or warrants granted.

During the month the following common shares were issued:

| Type              | Common shares issued |
|-------------------|----------------------|
| Stock Options     | nil                  |
| Warrant exercises | nil                  |

15. Provide details of any loans to or by Related Persons.

There were no new loans to, or by, Related Persons during the month.

16. Provide details of any changes in directors, officers or committee members.

There were no changes in directors, officers or committee members, during the month.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None to report.

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated Sep 5, 2022\_\_\_\_\_.

Rav Mlait  
Name of Director or Senior Officer  
(signed) "Rav Mlait"  
Signature

Chief Executive Officer  
Official Capacity

|                                 |                          |                       |
|---------------------------------|--------------------------|-----------------------|
| <b>Issuer Details</b>           | For Month End            | Date of Report        |
| Name of Issuer                  |                          | YY/MM/DD              |
| Cannabix Technologies Inc.      | Aug                      | 2022/09/05            |
| Registered Address              |                          |                       |
| 501 - 3292 Production Way       |                          |                       |
| City/Province/Postal Code       | Issuer Fax No.           | Issuer Telephone No.  |
| Burnaby, BC, V5A 4R4            | N/A                      | 604-551- 7 8 31       |
| Contact Name                    | Contact Position         | Contact Telephone No. |
| Rav Mlait                       | CEO                      | 604-551- 7 8 31       |
| Contact Email Address           | Web Site Address         |                       |
| info@ cannabixtechnologies. com | cannabixtechnologies.com |                       |

### \*Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built, work successfully or proceed. There is no assurance that existing "patent pending" technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.